aSyn Propagation Suppressor (aSyn Programs umbrella)

Single-program entity page for the small-molecule aSyn Propagation Suppressor / aSyn Degrader axis under the aSyn programs nav root. Promoted from the therapeutic-programs Entity Backlog. Per-axis α-synuclein narrative continues to live on alpha-synuclein § Antibody and Immunotherapy Programs / SNCA-Knockdown Programs (umbrella); this page collects the program-level evidence package across the single primary source page indexed under the program nav-root. This entity is not a meta-page over the sibling tak-341, snca-aso-wave, or snca-btv-hdo programs — those are separately owned program entities with their own Source Tables; this page covers only the SM Propagation Suppressor / aSyn Degrader axis recorded on 20240722_181827 (the source page also carries a top-of-page portfolio-grid fragment listing SMOL alongside SNCA BTV and SNCA-ASO (WAVE), and an SM-vs-αS-mAb-vs-ASO/NAM differentiation comparison; both are treated as in-source evidence rather than as sibling-program narrative). Every substantive statement links back to a source note or the canonical by-photo Markdown. Where the source carries Uncertain Spans, that uncertainty is preserved here rather than smoothed out.

Program Overview

The aSyn programs > aSyn Propagation Suppressor umbrella records two related small-molecule axes against α-synuclein: a phenotypic-screen SM (small-molecule) propagation suppressor track (aSyn propagation suppressor (phenotypic screening) (=SMOL) per the top-of- page portfolio-grid row) and an aSyn Degrader sub-axis. Both axes are anchored to the single source page (20240722_181827); the entity does not span additional program nav-roots, and the source page does not record a program code or program lead for either axis.

The source page captures four artifact bands on this axis. The first is the Old Portfolio Entry milestone grid under the heading Program start as the point for formalizing alignment ("Old Portfolio Entry"), a phase grid spanning Target Entry → Program Start ✓ → Lead Gen Entry → Portfolio Entry → Candidate Nomination → Candidate Selection → Early Develop Entry → IND → Early PoC with Decision Making Body rows (PRC / RSLT / PRC / PRC), Cumulative Cost from 1 oku¥ (Target Entry) through 5 oku¥ / 3 oku¥ (Program Start, two values overlap in the same column — preserved verbatim per source Uncertain Spans) and 11 / 21 / 24 / 30 oku¥ toward Early Develop Entry, and Cumulative Time from 1-2 yrs to 6.5-9.3 yrs; the page also carries the linear-timeline text strip Target Validation → Hit to Lead → Lead Generation → Lead Optimization → Pre-CS → Development Candidate → Phase 1 → Phase 2 with overlay spans ← 1.5-2.5 years →, ←─── 4-6 years from IND ───, and ←─── 5.5-7.5 years from IND ─── (20240722_181827).

The second band is the aSyn Degrader patient-selection narrative — the source rows Can we just target pathologic aSyn - (pSyn may not be tractible), oligomeric aSyn/, Native aSyn is monomeric and helical oligomeric, PATIENT selection: all should have all forms., DLB (amygdala, eg. SPAL), heterogeneity' PD, and {Strohäker, 2019 #1785} there was a greater structural heterogeneity among α-syn fibrils from the PD brain compared (fig6) (20240722_181827).

The third band is the aSyn Propagation Suppressor in-vitro model set plus the Expected MOA of HIT molecules pathway diagram. The in-vitro models are recorded as Mouse primary cortical neurons (arnu) + (mouse) aSyn PFF (primary screen) and (2ndary assay,) (SNCA mutation-derived) iPS-Dopaminergic neuron + (mouse or human) aSyn PFF (secondary assay), each row reading the patient-selection background Native aSyn is monomeric and helical oligomeric, PATIENT selection: all should have all forms., DLB (amygdala, eg. SPAL), and heterogeneity' PD vs MSA. The Expected MOA pathway diagram (annotated Modified from Neurobiol Dis, 2018, 109: 219) walks the spreading pathway nodes — Internalization, Extracellular release, the receptor row HSPGs / LAG3 / Other Receptors / Receptor clustering, Early endosome → Late endosome → Lysosome, LRRK2 / VPS35 / GBA, Exosome release, Exocytosis of α-syn, nanotube, 1st Neuron / 2nd Neuron, PFF neuron — and the six red callouts at which the SM HIT-molecule MOA is expected to act: Extracellular trap, Internalization inhibition, Aggregation inhibition, SNCA/α-syn reduction, Degradation enhancement, Secretion inhibition, Transmission inhibition (20240722_181827).

The fourth band is the Targets strip (some targets from PFF-based screen in mouse primary neuron (Asyn pff in vitro) {Bieri, 2019 #1778}) and the in-source SM-vs-αS-mAb-vs-ASO/NAM differentiation comparison (Small molecule propagation suppressor is differentiated from other αS-targeting approach, also annotated Modified from Neurobiol Dis, 2018, 109: 219). The differentiation comparison is recorded as three modality cards (SM propagation suppressor, αS mAb, ASO/NAM), each with Strengths / Differentiation points and Risks / Issues row groupings; the αS mAb card’s Roche/prothema token (variant of Prothena) is preserved verbatim per source Uncertain Spans. The comparison reads as in-source evidence for the SM track, not as a re-narration of the sibling antibody / ASO programs, which are separately owned by tak-341, snca-aso-wave, and snca-btv-hdo (20240722_181827).

Source Scope And Boundary Notes

This entity is a single-source program: only 20240722_181827 carries the program nav root aSyn programs > aSyn Propagation Suppressor as its first nav_path entry, and it is the only page indexed under asyn-programs. The page is fully included for evidence; the program nav root is the first nav_path entry, so the strict “first nav_path entry == program nav root” rule applies without exception.

Adjacent material that is excluded / delegated from this entity:

• The α-synuclein Tier 1 page Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model (20240722_181818) and the α-synuclein Tier 1 page TAK-341 (MEDI1341) > Clinical studies (20240722_181822) carry the TAK-341 / MEDI1341 antibody program. The _181822 page is the immediate-preceding photo of _181827 (per the source’s related_photos > preceding_photo_continues_upper_portfolio_grid) and shares the upper portfolio-grid context, but the TAK-341 / MEDI1341 program is owned by tak-341 and is referenced via Related Pages rather than re-narrated here. The portfolio-grid fragment at the top of _181827 lists SMOL alongside SNCA BTV / SNCA-ASO (WAVE) but does not include a TAK-341 row in the visible cells.
• The α-synuclein Tier 1 page SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda) (20240722_181831) is the immediate-following photo of _181827 (per the source’s related_photos > following_photo_continues_targets_section) and is owned by snca-btv-hdo. The top-of-page portfolio-grid fragment on _181827 includes the row SNCA BTV (Brain Transport Vehicle: ASO/HDO + transferrin receptor (TfR) ligand): Maeda Ryota (SNCA HDO의 후예) (the TfR / transferrin-receptor token is recorded as a TfR (PaddleOCR) vs TTR (Apple) reading ambiguity — see Uncertainties Carried From Source); the SNCA BTV (HDO) program-level Evidence Package and Source Table live on the sibling entity rather than on this page.
• The α-synuclein Tier 1 page SNCA ASO (WAVE) > Clinical plan of SNCA ASO (20240722_181835) is the SNCA ASO (WAVE) program owned by snca-aso-wave. The top-of-page portfolio-grid fragment on _181827 includes the row SNCA-ASO (WAVE); the SNCA ASO (WAVE) program-level Evidence Package and Source Table live on the sibling entity rather than on this page.
• The cross-pipeline Pipeline-of-PD aSyn - Antibody / aSyn - Small molecules / aSyn - Vaccine competitor-inventory pages (20240722_184324, 20240722_184327, 20240722_184330) do not list a SM Propagation Suppressor / aSyn Degrader row; they cover passive antibodies, small-molecule aggregation / propagation modulators (e.g., T100-18 A, UCB0599 / minzasolmin, NPT200-11, Anle138b), and vaccines as competitor inventory rather than as the in-house SMOL / SM Propagation Suppressor axis. They remain owned by alpha-synuclein § Antibody and Immunotherapy Programs and by tak-341 for the TAK-341 / MEDI1341 cross-pipeline rows.
• The α-synuclein Tier 1 supplement pages Pipeline of GD & GBA-PD > Supplement > Assay Truncation > Structure of aSyn > Synapse and aSyn > TM for aSyn programs (20240722_182606) and Pipeline of GD & GBA-PD > Supplement > Synapse and aSyn > TM for aSyn programs > Turnover of aSyn > ATP13A2 (Park9) (20240722_182609) carry the TM for aSyn programs segment that the alpha-synuclein source boundary map § Synthesis Outline groups together with the aSyn programs umbrella thread. These pages sit on the Supplement aSyn structure / synapse / turnover axis rather than on the SM-portfolio axis; they are α-synuclein biology supplement pages for the broader aSyn programs topic discussion, not program-portfolio pages, and remain owned by alpha-synuclein § Foundational Biology — Distribution / Expression / Function / Structure / Synapse / Turnover / Homology / KO / Safety. They are referenced via Related Pages rather than re-narrated here.

The page does not appear under the Pipeline of GD & GBA-PD inherited-thread band in the nav_path (its first entry is aSyn programs — a free-standing program nav root, not a Pipeline of GD & GBA-PD > … > aSyn programs … sub-path), so the entity scope is unambiguously the single nav-rooted page.

Evidence Package

evidence area	source-captured detail	source
Top-of-page portfolio grid fragment	Three visible rows (only the SMOL / SNCA BTV / SNCA-ASO program cells contain visible text per the source’s format_notes): aSyn propagation suppressor (phenotypic screening) (=SMOL); SNCA BTV (Brain Transport Vehicle: ASO/HDO + transferrin receptor (TfR) ligand): Maeda Ryota (SNCA HDO의 후예); SNCA-ASO (WAVE). The portfolio-grid fragment is in-source evidence for the SMOL row’s place in the aSyn programs portfolio; the SNCA BTV / SNCA-ASO rows are referenced via Related Pages and owned by their sibling entities (see Source Scope And Boundary Notes).	20240722_181827
Old Portfolio Entry milestone grid — phase columns	Header strip Target Entry / Program Start ✓ / Lead Gen Entry / Portfolio Entry / Candidate Nomination / Candidate Selection / Early Develop Entry / IND / Early PoC; Purpose row populated only at Portfolio Entry: Commit to Medicine Discovery, Candidate Selection: Commit to Clinical Asset, and Early Develop Entry: Commit to Medicine Development; Decision Making Body row populated at Program Start: PRC, Candidate Selection: RSLT, Early Develop Entry: PRC, Early PoC: PRC.	20240722_181827
Old Portfolio Entry milestone grid — cumulative cost row	Target Entry: 1 oku¥; Program Start: 5 oku¥ and 3 oku¥ (two values appear in the same column and are preserved verbatim per source Uncertain Spans); Lead Gen Entry: 11 oku¥; Portfolio Entry: 21 oku¥; Candidate Nomination: 24 oku¥; Candidate Selection: 30 oku¥; Early Develop Entry / IND / Early PoC cells visibly blank. The unit glyph is preserved as oku¥ (Japanese yen) per source Uncertain Spans.	20240722_181827
Old Portfolio Entry milestone grid — cumulative time row	Target Entry: 1-2 yrs; Program Start: 2.0-3.5 yrs; Lead Gen Entry: 3.5-5.5 yrs; Portfolio Entry: 5.0-7.3 yrs; Candidate Nomination: 5.5-8.0 yrs; Candidate Selection: 6.5-9.3 yrs; Early Develop Entry / IND / Early PoC cells visibly blank.	20240722_181827
Old Portfolio Entry — linear-timeline overlay	Target Validation → Hit to Lead → Lead Generation → Lead Optimization → Pre-CS → Development Candidate → Phase 1 → Phase 2; overlay spans ← 1.5-2.5 years →, ←─── 4-6 years from IND ───, ←─── 5.5-7.5 years from IND ───.	20240722_181827
aSyn Degrader — patient selection rationale	Can we just target pathologic aSyn - (pSyn may not be tractible), oligomeric aSyn/; Native aSyn is monomeric and helical oligomeric; PATIENT selection: all should have all forms.; DLB (amygdala, eg. SPAL); heterogeneity' PD; {Strohäker, 2019 #1785} there was a greater structural heterogeneity among α-syn fibrils from the PD brain compared (fig6). The tractible / SPAL tokens are preserved verbatim per source Uncertain Spans.	20240722_181827
aSyn Propagation Suppressor — patient-selection lead-in	Native aSyn is monomeric and helical oligomeric; PATIENT selection: all should have all forms.; DLB (amygdala, eg. SPAL); heterogeneity' PD vs MSA — the propagation-suppressor block adds the vs MSA qualifier compared with the aSyn Degrader block.	20240722_181827
aSyn Propagation Suppressor — in vitro model set	Primary screen Mouse primary cortical neurons (arnu) + (mouse) aSyn PFF; secondary assay (2ndary assay,) (SNCA mutation-derived) iPS-Dopaminergic neuron + (mouse or human) aSyn PFF. The arnu parenthetical token is preserved verbatim per source Uncertain Spans.	20240722_181827
Expected MOA of HIT molecules — pathway nodes	Internalization; Extracellular release; receptor row HSPGs / LAG3 / Other Receptors / Receptor clustering; trafficking chain Early endosome → Late endosome → Lysosome; lysosomal-side proteins LRRK2 / VPS35 / GBA; release / spread nodes Exosome release, Exocytosis of α-syn, nanotube; cell labels 1st Neuron / 2nd Neuron, PFF neuron. Pathway diagram annotated Modified from Neurobiol Dis, 2018, 109: 219.	20240722_181827
Expected MOA of HIT molecules — red callouts	The diagram’s six red callout boxes label the MOA classes at which SM HIT molecules are expected to act: Extracellular trap, Internalization inhibition, Aggregation inhibition, SNCA/α-syn reduction, Degradation enhancement, Secretion inhibition, Transmission inhibition.	20240722_181827
Targets — PFF-based screen reference	some targets from PFF-based screen in mouse primary neuron (Asyn pff in vitro) {Bieri, 2019 #1778} — the Targets strip points to a PFF-based screen target set anchored on the {Bieri, 2019 #1778} reference; the source records the reference handle but not the target list itself, and the section continues into the following photo per the source’s related_photos > following_photo_continues_targets_section (20240722_181831).	20240722_181827
SM Propagation Suppressor differentiation card	Strengths / Differentiation points: SM is an orally available disease modification therapy.; Novel MOA can be targeted by phenotypic assay. Risks / Issues: Target ID would be necessary for PE or before. Comparison block annotated Modified from Neurobiol Dis, 2018, 109: 219.	20240722_181827
αS mAb differentiation card	Strengths / Differentiation points: Prasinezumab (Roche/prothema) has shown a positive sign in the clinic.; Pathology spreading process can be blocked by mAb.; Relatively safe profile is expected. Risks / Issues: It could be difficult to attach intracellular αS aggregates.; BBB penetration is considered low. The Roche/prothema token is preserved verbatim per source Uncertain Spans (OCR variant prothena).	20240722_181827
ASO/NAM differentiation card	Strengths / Differentiation points: Knocking down is a direct approach to reduce amount of αS.; Intracellular αS is affected by ASO. Risks / Issues: Brain distribution might be insufficient due to intrathecal administration.; It might result in side effect by lessening physiological function of αS.	20240722_181827

Key Source Interpretations

interpretation	source
The aSyn programs > aSyn Propagation Suppressor umbrella records two related small-molecule axes against α-synuclein on a single page: a phenotypic-screen SM (small-molecule) propagation suppressor track (with =SMOL label in the top-of-page portfolio-grid fragment) and an aSyn Degrader sub-axis. The source page does not record a program code, program lead, or distinct PRC milestone series for either axis; the Old Portfolio Entry milestone grid is recorded as the umbrella-level phase plan rather than as a per-axis schedule.	20240722_181827
The Old Portfolio Entry milestone grid is recorded in source as the umbrella’s phase plan, with Decision Making Body listed as PRC for Program Start ✓ / Early Develop Entry / Early PoC and RSLT for Candidate Selection. Cumulative Cost rises from 1 oku¥ (Target Entry) to 30 oku¥ (Candidate Selection) and Cumulative Time from 1-2 yrs (Target Entry) to 6.5-9.3 yrs (Candidate Selection); the Program Start cell records two cumulative-cost values (5 oku¥ and 3 oku¥) overlapping in the same column and is preserved verbatim per source Uncertain Spans rather than reconciled. The Early Develop Entry / IND / Early PoC cumulative-cost / cumulative-time cells are visibly blank in the source.	20240722_181827
The aSyn Degrader patient-selection narrative records DLB (amygdala, e.g. SPAL) as a candidate stratification anchor and flags that pSyn may not be tractible (source’s tractible spelling preserved per Uncertain Spans) and that Native aSyn is monomeric and helical oligomeric so that PATIENT selection: all should have all forms. The {Strohäker, 2019 #1785} reference is cited specifically to ground the heterogeneity' PD row in greater α-syn-fibril structural heterogeneity in PD brain.	20240722_181827
The aSyn Propagation Suppressor block extends the same patient-selection lead-in (Native aSyn is monomeric and helical oligomeric, PATIENT selection: all should have all forms., DLB (amygdala, eg. SPAL)) but adds the heterogeneity' PD vs MSA qualifier and pairs the rationale with two in-vitro models — Mouse primary cortical neurons (arnu) + (mouse) aSyn PFF (primary screen) and (SNCA mutation-derived) iPS-Dopaminergic neuron + (mouse or human) aSyn PFF (secondary assay). The arnu parenthetical is preserved per source Uncertain Spans.	20240722_181827
The Expected MOA of HIT molecules pathway diagram is the program’s MOA framing for the SM Propagation Suppressor track: it walks the spreading pathway (internalization, extracellular release, receptor row HSPGs / LAG3 / Other Receptors, endosome / lysosome trafficking, lysosomal-side proteins LRRK2 / VPS35 / GBA, exosome / nanotube release, 1st Neuron / 2nd Neuron, PFF neuron) and overlays six red callouts that label the MOA classes at which a HIT molecule is expected to act: Extracellular trap, Internalization inhibition, Aggregation inhibition, SNCA/α-syn reduction, Degradation enhancement, Secretion inhibition, Transmission inhibition. The diagram is annotated Modified from Neurobiol Dis, 2018, 109: 219 and the same source attribution appears on the SM-vs-αS-mAb-vs-ASO/NAM differentiation block.	20240722_181827
The Targets strip records the program’s target set as some targets from PFF-based screen in mouse primary neuron (Asyn pff in vitro) {Bieri, 2019 #1778}. The list of specific targets is not recorded on this page; the source’s related_photos > following_photo_continues_targets_section notes that the targets section continues into 20240722_181831 (the SNCA BTV (HDO) executive-summary page), but _181831 is owned by snca-btv-hdo and that owner page does not surface a SMOL / Propagation Suppressor target list either; downstream readers should treat the target set as bounded by the {Bieri, 2019 #1778} reference rather than enumerated in source.	20240722_181827
The SM-vs-αS-mAb-vs-ASO/NAM differentiation block records the in-source rationale for the SM Propagation Suppressor track relative to passive antibody and ASO/NAM modalities: SM is positioned as orally available disease modification therapy with Novel MOA can be targeted by phenotypic assay, with Target ID would be necessary for PE or before flagged as the SM-track risk; αS mAb is anchored on Prasinezumab (Roche/prothema) clinical signal with Pathology spreading process can be blocked by mAb and Relatively safe profile, balanced against intracellular-aggregate access and BBB penetration is considered low risks; ASO/NAM is positioned as direct approach to reduce amount of αS and Intracellular αS is affected by ASO, balanced against Brain distribution might be insufficient due to intrathecal administration and side effect by lessening physiological function of αS. The comparison reads as in-source evidence framing the SMOL track; the corresponding passive-antibody and ASO/HDO program pages live on tak-341, snca-aso-wave, and snca-btv-hdo respectively.	20240722_181827
The top-of-page portfolio-grid fragment records aSyn propagation suppressor (phenotypic screening) (=SMOL) alongside SNCA BTV (… TfR ligand): Maeda Ryota (SNCA HDO의 후예) and SNCA-ASO (WAVE). The =SMOL label and the SMOL row’s portfolio placement are recorded only on this page; the SNCA BTV / SNCA-ASO rows are also recorded on the page but their program-level evidence packages live on the sibling entity pages and are not duplicated here. The TfR / TTR token in the SNCA BTV row is preserved verbatim per source Uncertain Spans.	20240722_181827

Source Table

stem	nav path	source note	canonical	uncertain spans	embedded images
20240722_181827	aSyn programs > aSyn Propagation Suppressor	note	md	7	0

1 source; uncertain_span_count totals 7; embedded_image_count totals 0. The page records four figure-like artifacts in its format_notes (Old Portfolio Entry timeline figure, Expected MOA of HIT molecules pathway diagram, SM-vs-αS-mAb-vs-ASO/NAM differentiation diagram, top-of-page portfolio-grid fragment), but none of them are body-embedded — each is preserved as evidence-only because the available crop also contained surrounding table text or upper-cell text bleed-in (per the 2026-04-29 body-purity decision). The figure-like artifacts are listed below for navigation only and are not re-embedded on this entity page.

Figure / Asset Groups In Source

source

figure group

20240722_181827

Top-of-page portfolio-grid fragment (Word table region; not embedded — available as evidence-only figure_pipeline_fragment.jpg); Old Portfolio Entry timeline figure (Word process diagram with milestone columns, decision-making bodies, and cumulative cost / time rows; not embedded — available as evidence-only figure_program_start_timeline.jpg); Expected MOA of HIT molecules pathway diagram with red callout boxes and labels LAG3 / HSPGs / LRRK2 / VPS35 / GBA etc. (not embedded — available as evidence-only figure_expected_moa_hit_molecules.jpg); Small-molecule propagation suppressor differentiation diagram with three labelled boxes (SM propagation suppressor / αS mAb / ASO/NAM) and two pathway sub-diagrams (not embedded — box-internal text fully transcribed in body; available as evidence-only figure_asyn_targeting_differentiation.jpg).

Uncertainties Carried From Source

issue	source
SNCA BTV row TfR / transferrin-receptor ligand token: PaddleOCR reads TfR; Apple reads TTR; image looks closer to TfR. Preserved as TfR in transcription but flagged as a reading ambiguity.	20240722_181827
Cumulative-cost row unit glyph okuY / oku¥: glyph reads as Japanese yen ¥; preserved as oku¥ rather than okuY.	20240722_181827
Cumulative Cost Program Start cell records two values (5 oku¥ and 3 oku¥) overlapping in the same column; both preserved verbatim rather than reconciled.	20240722_181827
aSyn Degrader first row token tractible: visible spelling has tractible; may have intended tractable. Preserved verbatim.	20240722_181827
DLB (amygdala, eg. SPAL) row token SPAL: three letters small in the photo; could be SPAL or similar. Preserved verbatim.	20240722_181827
aSyn Propagation Suppressor in-vitro-model parenthetical token arnu after Mouse primary cortical neurons: small in the photo; preserved verbatim rather than guessed.	20240722_181827
αS mAb differentiation-card company token Roche/prothema: OCR variant was prothena; image appears closer to prothema. Preserved verbatim rather than normalised to Prothena.	20240722_181827

Related Pages

• alpha-synuclein — α-synuclein topic synthesis (Tier 1); the umbrella narrative for the aSyn programs umbrella lives under § Antibody and Immunotherapy Programs (aSyn programs > aSyn Propagation Suppressor axis lead) and under § SNCA-Knockdown Programs (umbrella).
• therapeutic-programs — program-routing map; this entity page is the canonical owner for the aSyn programs umbrella (aSyn Propagation Suppressor / aSyn Degrader) row that was previously listed as an Entity Backlog Candidate.
• alpha-synuclein-source-boundary — α-synuclein Tier 1 / Tier 2 / Tier 3 inclusion-and-delegation map; the aSyn programs umbrella is under Programs and Standalone Nav-Roots / aSyn programs umbrella — Propagation Suppressor, Degrader.
• asyn-programs — per-nav-root index for aSyn programs (1 source — the single aSyn programs > aSyn Propagation Suppressor page).
• gba-pd-asyn — section index containing the single source used here.
• source-catalog — all 447 sources in capture order.
• nav-path-index — 376 distinct nav_paths.
• tak-341 — sibling α-synuclein program entity (passive-immunotherapy modality; the _181822 Clinical studies page is the immediate-preceding photo of _181827 and shares the upper portfolio-grid context; the SM-vs-αS-mAb differentiation card on _181827 references Prasinezumab (Roche/prothema) as the αS mAb anchor without re-narrating the TAK-341 / MEDI1341 program).
• snca-aso-wave — sibling SNCA- knockdown program entity (RNase-H ASO modality; the top-of-page portfolio-grid fragment on _181827 lists the SNCA-ASO (WAVE) row and the SM-vs-ASO/NAM differentiation card frames the SMOL track against the ASO/NAM modality without re-narrating the SNCA ASO (WAVE) program).
• snca-btv-hdo — sibling SNCA- knockdown program entity (HDO + BTV modality; the _181831 Executive summary page is the immediate-following photo of _181827 and continues the Targets section per the source’s related_photos; the top-of-page portfolio-grid fragment on _181827 lists the SNCA BTV (… TfR ligand): Maeda Ryota (SNCA HDO의 후예) row).
• parkn-gt — sibling program entity (different modality class; same in-house program-entity precedent).
• nlrp3-inhibitor — sibling program entity (small-molecule modality; same program-entity precedent).
• pr001 — pilot-scope GBA gene-therapy program entity (sibling within the GBA-PD pilot).